Literature DB >> 32572804

Similar risk of cardiovascular events in idiopathic inflammatory myopathy and rheumatoid arthritis in the first 5 years after diagnosis.

Cristina Párraga Prieto1, Fowzia Ibrahim2, Richard Campbell2, Hector Chinoy3,4, James Galloway2, Patrick Gordon2.   

Abstract

OBJECTIVES: To estimate the incidence of cardiovascular (CV) events in idiopathic inflammatory myopathy (IIM) compared to patients with rheumatoid arthritis (RA) and the general population. To explore the contribution of traditional CV risk factors to any difference observed.
METHODS: A retrospective matched population-based cohort study was conducted using UK Clinical Practice Research Datalink (CPRD) from 1987 to 2013. The incidence of CV events was calculated for each cohort over time and compared using Cox proportional hazards models. Multivariable analyses were used to adjust for traditional CV risk factors.
RESULTS: A total of 603 patients with IIM 4047 RA and 4061 healthy controls were included. The rate of CV events in IIM was significantly greater than healthy controls [hazard ratio (HR) 1.47 (95% confidence interval (CI) 1.18-1.83)] and remained significant after adjustment for CV risk factors [HR 1.38 (95% CI 1.11-1.72)]. Risk was similar between IIM and RA [HR 1.01 (95% CI 0.78-1.31)]. The rate of myocardial infarction [HR 1.61 (95% CI 1.27-2.04)] but not stroke [HR 0.92 (95% CI 0.59-1.44)] was significantly greater in IIM compared to healthy controls. After the first 5 years, the rate of CV events for RA remained significantly greater compared to the control group, but appeared to return to that of the healthy controls in the IIM group.
CONCLUSION: IIM is associated with an increased risk of CV events in the first 5 years after diagnosis similar to that of RA. Beyond 5 years, the risk appears to return to that of the general population in IIM but not RA. Key Points • The excess risk of cardiovascular events in IIM is similar to that found in RA. • The excess risk of cardiovascular events is greatest in the first 5 years after diagnosis.

Entities:  

Keywords:  Atherosclerosis; Cardiovascular event; Dermatomyositis; Idiopathic inflammatory myopathy; Polymyositis

Mesh:

Year:  2020        PMID: 32572804      PMCID: PMC7782367          DOI: 10.1007/s10067-020-05237-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  38 in total

1.  Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study.

Authors:  Sharan K Rai; Hyon K Choi; Eric C Sayre; J Antonio Aviña-Zubieta
Journal:  Rheumatology (Oxford)       Date:  2015-09-30       Impact factor: 7.580

2.  Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  J M Esdaile; M Abrahamowicz; T Grodzicky; Y Li; C Panaritis; R du Berger; R Côte; S A Grover; P R Fortin; A E Clarke; J L Senécal
Journal:  Arthritis Rheum       Date:  2001-10

3.  Decreased flow-mediated dilatation with increased arterial stiffness and thickness as early signs of atherosclerosis in polymyositis and dermatomyositis patients.

Authors:  Melinda Vincze; H Dér; Gy Kerekes; P Szodoray; M Zeher; K Dankó; P Soltész
Journal:  Clin Rheumatol       Date:  2014-03-12       Impact factor: 2.980

4.  The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease.

Authors:  Lihi Eder; Vinod Chandran; Dafna D Gladman
Journal:  Ann Rheum Dis       Date:  2013-07-25       Impact factor: 19.103

Review 5.  Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications.

Authors:  Bryant R England; Geoffrey M Thiele; Daniel R Anderson; Ted R Mikuls
Journal:  BMJ       Date:  2018-04-23

6.  The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis.

Authors:  Cynthia M Magro; Jeremy P Segal; A Neil Crowson; Paul Chadwick
Journal:  J Cutan Pathol       Date:  2009-11-04       Impact factor: 1.587

7.  Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool.

Authors:  Helga Sanner; Ivar Sjaastad; Berit Flatø
Journal:  Rheumatology (Oxford)       Date:  2014-03-31       Impact factor: 7.580

Review 8.  Atherosclerosis in rheumatoid arthritis: is it all about inflammation?

Authors:  Sarah Skeoch; Ian N Bruce
Journal:  Nat Rev Rheumatol       Date:  2015-03-31       Impact factor: 20.543

9.  Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey.

Authors:  Eleni Linos; David Fiorentino; Bharathi Lingala; Eswar Krishnan; Lorinda Chung
Journal:  Arthritis Res Ther       Date:  2013-01-08       Impact factor: 5.156

Review 10.  Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies.

Authors:  Thomas Schwartz; Louise Pyndt Diederichsen; Ingrid E Lundberg; Ivar Sjaastad; Helga Sanner
Journal:  RMD Open       Date:  2016-09-27
View more
  2 in total

1.  Coronary Heart Disease and Cardiovascular Risk Factors in Patients With Idiopathic Inflammatory Myopathies: A Systemic Review and Meta-Analysis.

Authors:  Li Qin; Fang Li; Qiang Luo; Lifang Chen; Xiaoqian Yang; Han Wang
Journal:  Front Med (Lausanne)       Date:  2022-01-14

2.  British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy.

Authors:  Alexander G S Oldroyd; James B Lilleker; Tania Amin; Octavio Aragon; Katie Bechman; Verna Cuthbert; James Galloway; Patrick Gordon; William J Gregory; Harsha Gunawardena; Michael G Hanna; David Isenberg; John Jackman; Patrick D W Kiely; Polly Livermore; Pedro M Machado; Sue Maillard; Neil McHugh; Ruth Murphy; Clarissa Pilkington; Athiveeraramapandian Prabu; Phoebe Rushe; Stefan Spinty; Joanne Swan; Hasan Tahir; Sarah L Tansley; Paul Truepenny; Yvonne Truepenny; Kishore Warrier; Mark Yates; Charalampia Papadopoulou; Neil Martin; Liza McCann; Hector Chinoy
Journal:  Rheumatology (Oxford)       Date:  2022-05-05       Impact factor: 7.046

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.